Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

NEXT STORY
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
PREV STORY
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

author_avatar
NASDAQ Market News

Sera Prognostics Completes $100 Million Series E Financing

author_avatar
NASDAQ Market News